Biogen adds patent for multiple sclerosis drug Tecfidera

03/20/2013 | Reuters

Biogen Idec obtained a new patent for its multiple sclerosis drug Tecfidera, which could receive FDA approval this month. The patent on a daily dosing regimen of 480 milligrams is due to expire in 2028.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA